Therapeutic landscape and future direction of metastatic colorectal cancer
H Bando, A Ohtsu, T Yoshino - Nature Reviews Gastroenterology & …, 2023 - nature.com
In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …
Stage IV colorectal cancer management and treatment
O Hernandez Dominguez, S Yilmaz… - Journal of Clinical …, 2023 - mdpi.com
(1) Background: Colorectal cancer (CRC) is the third most common cancer and the second
leading cause of cancer-related mortality worldwide. Up to 50% of patients with CRC …
leading cause of cancer-related mortality worldwide. Up to 50% of patients with CRC …
Long-term survival, prognostic factors, and selection of patients with colorectal cancer for liver transplant: a nonrandomized controlled trial
S Dueland, TM Smedman, T Syversveen, H Grut… - JAMA …, 2023 - jamanetwork.com
Importance Liver transplant for colorectal cancer with liver metastases was abandoned in
the 1990s due to poor overall survival. From 2006, liver transplant for in nonresectable …
the 1990s due to poor overall survival. From 2006, liver transplant for in nonresectable …
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic …
PURPOSE The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating
encorafenib+ cetuximab+ binimetinib in previously treated patients with BRAF V600E …
encorafenib+ cetuximab+ binimetinib in previously treated patients with BRAF V600E …
Practice-level variation in molecular testing and use of targeted therapy for patients with non–small cell lung cancer and colorectal cancer
Importance All patients with newly diagnosed non–small cell lung cancer (NSCLC) and
colorectal cancer (CRC) should receive molecular testing to identify those who can benefit …
colorectal cancer (CRC) should receive molecular testing to identify those who can benefit …
Colorectal cancer: Genetic alterations, novel biomarkers, current therapeutic strategies and clinical trails
Colorectal cancer (CRC) is the third most commonly detected cancer with a serious global
health issue. The rates for incidence and mortality for CRC are alarming, especially since …
health issue. The rates for incidence and mortality for CRC are alarming, especially since …
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO …
S Stintzing, K Heinrich, D Tougeron… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE BRAF V600E mutation is associated with a poor outcome in metastatic colorectal
cancer (mCRC). This clinical trial investigated the efficacy of triplet chemotherapy …
cancer (mCRC). This clinical trial investigated the efficacy of triplet chemotherapy …
Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: A systematic review and meta‑analysis
LL Jia, JX Zhao, LP Zhao, JH Tian, G Huang - European Journal of …, 2023 - Elsevier
Purpose The purpose of this study was to evaluate the methodological quality of radiomics-
based studies for noninvasive, preoperative prediction of Kirsten rat sarcoma (KRAS) …
based studies for noninvasive, preoperative prediction of Kirsten rat sarcoma (KRAS) …
The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter …
HL Tsai, CC Lin, YC Sung, SH Chen, LT Chen… - British Journal of …, 2023 - nature.com
Background Patients treated with anti-epidermal growth factor receptor (anti-EGFR) will
ultimately develop acquired resistance promoted by clonal selection, mainly the emergence …
ultimately develop acquired resistance promoted by clonal selection, mainly the emergence …
[HTML][HTML] The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas
Despite being in the same pathway, mutations of KRAS and BRAF in colorectal carcinomas
(CRCs) determine distinct progression courses. ZEB1 induces an epithelial-to-mesenchymal …
(CRCs) determine distinct progression courses. ZEB1 induces an epithelial-to-mesenchymal …